PROSTATE CANCER Predicting prostate biopsy results-PCA3 versus phi

被引：10
|
作者：
Loeb, Stacy [1 ,2 ]
机构：
[1] NYU, Dept Urol, New York, NY 10016 USA
[2] NYU, Manhattan Vet Affairs Med Ctr, New York, NY 10016 USA
来源：
NATURE REVIEWS UROLOGY | 2015年 / 12卷 / 03期
关键词：
ACTIVE SURVEILLANCE; ANTIGEN;
D O I：
10.1038/nrurol.2015.1
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Data comparing tests designed to predict the likelihood of finding significant prostate cancer on biopsy are limited. A comparison of two such tests—the Prostate Health Index (phi) and prostate cancer antigen 3 (PCA3) score—has found that phi outperforms PCA3 for predicting clinically significant prostate cancer.
引用
收藏
页码：130 / 131
页数：2
相关论文
共 50 条
  • [1] Diagnostic performance of prostate health index (PHI) in predicting prostate cancer on prostate biopsy
    Othman, Hanita
    Abu Yamin, Azzah Hana
    Isa, Nurismah M. D.
    Bahadzor, Badrulhisham
    Zakaria, Syed Zulkifli Syed
    MALAYSIAN JOURNAL OF PATHOLOGY, 2020, 42 (02) : 209 - 214
  • [2] PSA, PCA3 and the phi losophy of prostate cancer management
    Melichar, Bohuslav
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2013, 51 (04) : 707 - 712
  • [3] External validation of a PCA-3-based nomogram for predicting prostate cancer and high-grade cancer on initial prostate biopsy
    Greene, Daniel J.
    Elshafei, Ahmed
    Nyame, Yaw A.
    Kara, Onder
    Malkoc, Ercan
    Gao, Tianming
    Jones, J. Stephen
    PROSTATE, 2016, 76 (11): : 1019 - 1023
  • [4] PHI AND PCA3 SIGNIFICANTLY IMPROVE DIAGNOSTIC ACCURACY IN PATIENTS UNDERGOING PROSTATE BIOPSY
    Perdona, Sisto
    Quarto, Giuseppe
    Sorrentino, Domenico
    De Domenico, Renato
    Cariati, Federica
    Sorrentino, Alessandra
    Terracciano, Daniela
    Mazzarella, Claudia
    Marino, Ada
    Armellino, Carla
    Di Girolamo, Antonio
    Montanino, Florestano
    Vincenzo, Altieri
    Bruzzese, Dario
    Ferro, Matteo
    ANTICANCER RESEARCH, 2012, 32 (05) : 1920 - 1920
  • [5] Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients
    Goode, Roland R.
    Marshall, Susan J.
    Duff, Michael
    Chevli, Eric
    Chevli, K. Kent
    PROSTATE, 2013, 73 (01): : 48 - 53
  • [6] Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy
    Rubio-Briones, Jose
    Borque, Angel
    Esteban, Luis M.
    Casanova, Juan
    Fernandez-Serra, Antonio
    Rubio, Luis
    Casanova-Salas, Irene
    Sanz, Gerardo
    Dominguez-Escrig, Jose
    Collado, Argimiro
    Gomez-Ferrer, Alvaro
    Iborra, Inmaculada
    Ramirez-Backhaus, Miguel
    Martinez, Francisco
    Calatrava, Ana
    Lopez-Guerrero, Jose A.
    BMC CANCER, 2015, 15
  • [7] Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy
    Ochiai, Atsushi
    Okihara, Koji
    Kamoi, Kazumi
    Oikawa, Takehiro
    Shimazui, Toru
    Murayama, Shin-Ichiro
    Tomita, Kyoichi
    Umekawa, Tohru
    Uemura, Hirotsugu
    Miki, Tsuneharu
    BJU INTERNATIONAL, 2013, 111 (06) : 928 - 933
  • [8] PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy
    Elshafei, Ahmed
    Chevli, K. Kent
    Moussa, Ayman S.
    Kara, Onder
    Chueh, Shih-Chieh
    Walter, Peter
    Hatem, Asmaa
    Gao, Tianming
    Jones, J. Stephen
    Duff, Michael
    PROSTATE, 2015, 75 (16): : 1951 - 1957
  • [9] The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting
    Adam, Ahmed
    Engelbrecht, Matthys J.
    Bornman, Maria S.
    Manda, Samuel O.
    Moshokoa, Evelyn
    Feilat, Rasmi A.
    BJU INTERNATIONAL, 2011, 108 (11) : 1728 - 1733
  • [10] Biopsy and Radical Prostatectomy Pathological Patterns Influence Prostate Cancer Gene 3 (PCA3) Score
    De Luca, Stefano
    Passera, Roberto
    Bollito, Enrico
    Milillo, Angela
    Scarpa, Roberto Mario
    Papotti, Mauro
    Coda, Renato
    Randone, Donato Franco
    ANTICANCER RESEARCH, 2013, 33 (10) : 4657 - 4662
12345